Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls
Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls
复制标题
DOI：
10.1002/cncr.20608
复制
发表时间：
2004-11-01
期刊：
影响因子：
6.2
通讯作者：
Potosky, AL
中科院分区：
文献类型：
--
作者：
Hoffman, RM;Gilliland, FD;Potosky, AL
背景前列腺癌和治疗影响健康相关的生活质量（HRQOL）。作者前瞻性地比较了前列腺癌病例与年龄匹配和种族匹配的对照组之间的前列腺和总体HRQOL。病例组包括293名局限性前列腺癌男性，他们从基于人群的新墨西哥州肿瘤登记处随机选择，对照组包括618名男性，他们从管理数据库中随机选择，年龄和种族匹配。受试者完成了人口统计学、社会经济状况、合并症、前列腺和一般HRQOL的基线调查。210例（71.7%）和421例（67.8%）对照组在5年后完成了随访。多项逻辑回归模型比较了基线特征以及通过医学结局研究SF-36的选定领域测量的5年总体HRQOL结局。作者使用混合模型重复测量方差分析和多项式回归分析来比较两组之间泌尿、肠道和性功能的纵向变化。基线时，前列腺癌患者的排尿控制和性功能优于对照组。5年后，对照组的性功能显著下降，但排尿功能保持稳定。然而，癌症患者随后报告这两个领域的显着下降，并留下了更差的功能和更多的麻烦比对照组。随访时两组的肠功能和总体HRQOL相似。前列腺癌治疗导致5年的排尿和性功能显著下降，远远超过对照组的年龄相关变化。癌症患者在HRQOL的这些疾病特异性领域的功能明显差于对照组，并且比对照组更麻烦。肠功能和总体HRQOL不受癌症状态的影响。2004年由美国癌症协会出版。
BACKGROUND. Prostate carcinoma and treatments affect health-related quality of life (HRQOL). The authors prospectively compared prostate and general HRQOL between prostate carcinoma cases and an age-matched and ethnicity-matched control group.METHODS. The case cohort consisted of 293 men with localized prostate carcinoma who were selected randomly from the population-based New Mexico Tumor Registry, and the control cohort consisted of 618 men who were selected randomly from administrative databases and matched for age and ethnicity. Subjects completed a baseline survey of demographics, socioeconomic status, comorbidity, and prostate and general HRQOL. Also, 210 cases (71.7%) and 421 controls (67.8%) completed a follow-up survey 5 years later. Multinomial logistic regression models compared baseline characteristics as well as 5-year general HRQOL outcomes measured by selected domains of the Medical Outcomes Study SF-36. The authors used a mixed-model repeated-measures analysis of variance and multinomial regression analyses to compare longitudinal changes in urinary, bowel, and sexual function between groups.RESULTS. At baseline, patients with prostate carcinoma had better urinary control and sexual function than controls. Over 5 years, sexual function declined significantly among controls, although urinary function remained stable. However, patients with cancer subsequently reported significant declines in both domains and were left with much worse function and more bother than controls. Bowel function and general HRQOL were similar for both groups at follow-up.CONCLUSIONS. Prostate carcinoma treatment led to significant 5-year declines in urinary and sexual function that far exceeded age-related changes in controls. Patients with cancer had significantly worse function and more bother than controls for these disease-specific domains of HRQOL. Bowel function and general HRQOL were not affected by cancer status. Published 2004 by the American Cancer Society.*